Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083904 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sepideh Mokhtari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Neurotoxicity Syndromes, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe immune effector cell-associated neurotoxicity syndrome (ICANS) occurs in about 30% of all patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel). There are currently limited treatment strategies other than the standard corticosteroids, and it is essential to find additional therapies to manage severe ICANS. We conducted a retrospective study of neurologic outcomes among patients who received axi-cel for LBCL from May 2015 to February 2019. We identified patients who developed severe ICANS and were treated with glucocorticoids followed by intravenous immunoglobulin (IVIG) (n = 9) or glucocorticoids alone (n = 10). There was no statistically significant difference in the time to resolution (TTR) of severe ICANS between groups; however, patients in the IVIG had more severe grades of ICANS with a lower performance status at baseline. The cumulative steroid days were 11.2 in the IVIG arm and 13.5 in the glucocorticoids-only arm. The use of IVIG for severe ICANS after axi-cel therapy was tolerable and safe and is generally recommended in the CAR-T setting in patients with hypogammaglobinemia. The use of IVIG as a potential therapeutic agent for severe ICANS can be further explored in future prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
- Department of Medical Oncology, Aspirus Cancer Care, Wausau, WI 54401, USA.
- Department of Bone Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA.
- Department of Biostatistics, Moffitt Cancer Center, Tampa, FL 33612, USA.
- Department of Medical Oncology, John Hopkins Hospital, Washington, DC 20016, USA.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
ORCID-Profile: Syeda Saba Kareem, Rawan G Faramand, Marco L Davila, Peter A Forsyth
Zitieren
APA
Mokhtari, S., Asquith, J. M., Kareem, S. S., Bachmeier, C. A., Pina, Y., Faramand, R. G., Kim, Y., Peguero, E. N., Sahebjam, S., Jaffer, M. H., Iacono, D. P., Jain, M. D., Vogelbaum, M. A., Davila, M. L., Forsyth, P. A., Locke, F. L., & Lazaryan, A. (2025). Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083904
Vancouver
Mokhtari S, Asquith JM, Kareem SS, Bachmeier CA, Pina Y, Faramand RG, et al. Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083904
BibTeX
@article{Mokhtari2025,
author = {Mokhtari, Sepideh and Asquith, Justin M and Kareem, Syeda Saba and Bachmeier, Christina A and Pina, Yolanda and Faramand, Rawan G and Kim, Youngchul and Peguero, Edwin N and Sahebjam, Solmaz and Jaffer, Mohammad H and Iacono, David P and Jain, Michael D and Vogelbaum, Michael A and Davila, Marco L and Forsyth, Peter A and Locke, Frederick L and Lazaryan, Aleksandr},
title = {Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083904}
}
EUVIMED